Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Erik Wilson

Surgery Bellaire, TX Medical Doctor

NPI 1881624237 CMS profile 85122

6500 West Loop S Ste 200E, Bellaire, TX 77401

Open in the dashboard

General payments

$610,054

742 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$612,171 paid to institutions, not to them · program year 2025

Through program year 2025, Erik Wilson of Bellaire, TX is reported in the CMS Open Payments database as having received $610,054 across 742 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $612,171 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $99,510 119
2024 General $73,815 116
2023 General $118,036 118
2022 General $68,139 91
2021 General $47,914 82
2020 General $67,375 58
2019 General $135,265 158

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erik Wilson
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Erik Wilson were reported at $99,510. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Erik Wilson Surgery median Middle half National median
2019 $135,265 $253 $82–$1,521 $163
2020 $67,375 $131 $40–$706 $114
2021 $47,914 $168 $50–$904 $132
2022 $68,139 $224 $76–$1,218 $149
2023 $118,036 $253 $82–$1,255 $160
2024 $73,815 $279 $90–$1,381 $164
2025 $99,510 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ethicon Inc. $150,378 82 payments
  2. Intuitive Surgical, Inc. $148,639 147 payments
  3. W. L. Gore & Associates, Inc. $136,336 160 payments
  4. Medtronic, Inc. $39,004 93 payments
  5. Boston Scientific Corporation $37,216 65 payments
  6. Medical Device Business Services, Inc. $20,573 10 payments
  7. CMR Surgical, Inc. $19,568 19 payments
  8. Olympus Corporation of the Americas $15,955 13 payments
  9. Olympus America Inc. $12,446 16 payments
  10. Covidien LP $7,870 18 payments
  11. Other $22,069 119 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $230,788 60 payments
  2. Education $140,090 49 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $91,213 48 payments
  4. Travel and Lodging $66,369 211 payments
  5. Honoraria $49,928 11 payments
  6. Food and Beverage $31,665 363 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $148,639 147 payments
  2. GORE SEAMGUARD Bioabsorbable Staple Line Reinforce $60,968 83 payments
  3. SEAMGUARD Staple Line Reinforcement $31,236 16 payments
  4. GORE BIO-A Tissue Reinforcement $27,375 13 payments
  5. GORE ENFORM Preperitoneal Biomaterial $26,672 12 payments
  6. SEAMGUARD Bioabsorbable Staple Line Reinforcement $21,513 31 payments
  7. GORE SYNECOR Biomaterial $20,328 4 payments
  8. Versius Surgical System (Versius Plus) $19,568 19 payments
  9. Harmonic $15,181 4 payments
  10. Endopath Xcel $14,880 1 payment
  11. Other $140,679 304 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$19,832

Medicare's payments for the services billed

Medicare patients

61

Average age 70

Services billed

118

31 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 34%
Depression 33%
Diabetes 28%
Osteoporosis 26%
Atrial fibrillation 25%
Chronic kidney disease 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

742 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record